Elsevier

Sleep Medicine

Volume 9, Issue 6, August 2008, Pages 652-659
Sleep Medicine

Original Article
Bi-level positive pressure ventilation and adaptive servo ventilation in patients with heart failure and Cheyne-Stokes respiration

https://doi.org/10.1016/j.sleep.2007.09.008Get rights and content

Abstract

Objectives

Nocturnal positive pressure ventilation (PPV) has been shown to be effective in patients with impaired left ventricular ejection fraction (LVEF) and Cheyne-Stokes respiration (CSR). We investigated the effect of a bi-level PPV and adaptive servo ventilation on LVEF, CSR, and quantitative sleep quality.

Methods

Thirty-seven patients (New York heart association [NYHA] II–III) with LVEF < 45% and CSR were investigated by electrocardiography (ECG), echocardiography and polysomnography. The CSR index (CSRI) was 32.3 ± 16.2/h. Patients were randomly treated with bi-level PPV using the standard spontaneous/timed (S/T) mode or with adaptive servo ventilation mode (AutoSetCS). After 6 weeks, 30 patients underwent control investigations with ECG, echocardiography, and polysomnography.

Results

The CSRI decreased significantly to 13.6 ± 13.4/h. LVEF increased significantly after 6 weeks of ventilation (from 25.1 ± 8.5 to 28.8 ± 9.8%, p < 0.01). The number of respiratory-related arousals decreased significantly. Other quantitative sleep parameters did not change. The Epworth sleepiness score improved slightly. Daytime blood pressure and heart rate did not change. There were some differences between bi-level PPV and adaptive servo ventilation: the CSRI decreased more in the AutoSetCS group while the LVEF increased more in the bi-level PPV group.

Conclusions

Administration of PPV can successfully attenuate CSA. Reduced CSA may be associated with improved LVEF; however, this may depend on the mode of PPV. Changed LVEF is evident even in the absence of significant changes in blood pressure.

Introduction

Sleep-related breathing disorders are effectively treated with positive pressure ventilation (PPV) therapy. Not only patients with obstructive sleep apnea (OSA) benefit from this therapy but also patients with central sleep-related breathing disorders. Central sleep-related breathing disorders and Cheyne-Stokes respiration (CSR) in particular are common in patients with heart failure. Approximately 40% of patients with an impaired left ventricular ejection fraction (LVEF) suffer from central sleep-related breathing disorders, which increases their mortality [1], [2], [3], [4].

To reduce mortality and improve quality of life, sleep-related breathing disorders should be treated in patients with heart failure. Oxygen therapy can reduce CSR to a limited extent only [5]. The application of respiratory stimulants, carbon dioxide and atrial overdrive pacing are further means of treatment. Continuous positive airway pressure (CPAP) has proven to reduce CSR [6], [7], [8] and to improve LVEF when controlled after 1–3 months [3], [9]. This beneficial effect has been shown in patients with chronic heart failure (CHF) and OSA as well [10], [11].

In contrast, the Canadian positive airway pressure (CANPAP) trial showed that conventional CPAP decreased AHI only by 50% and CPAP was only tolerated for 3.5 h/night [12]. When considering the CPAP responder with an AHI below 15/h, this treatment was effective in abolishing CSR and improving LVEF and transplant-free survival [8]. The CANPAP study did not demonstrate improvements in sleep quality nor in the number of nocturnal arousals. Due to this negative result and due to the persistent clinical need to effectively reduce central apneas and to improve patient comfort, the search for alternative treatment modes besides CPAP [13] motivated this study.

Bi-level PPV is an alternative ventilation mode for patients with impaired LVEF and CSR [14]. Similar to data with CPAP, a few studies using bi-level PPV indicated that this ventilation mode can effectively reduce CSR, improve sleep quality, and increase LVEF in CHF patients [15], [16], [17], [18]. With the new ventilation technique, adaptive servo ventilation (ASV), similar positive effects on CSR and sleep quality were reported [16], [19], [20]. Pepperell et al. [20] did not report an effect on LVEF after 1 month of ASV support in CHF patients with central sleep apnea, although a significant decrease in brain natriuretic peptide (BNP) was observed. In contrast, Philippe et al. [19] reported for the first time an increase of LVEF over a period of 6 months in their ASV group compared to CPAP treated CHF patients.

Still results are contradicting regarding cardiovascular outcome and sleep characteristics with ASV therapy. More specifically, there are very few studies using bi-level PPV in CHF patients. For a selected patient population with heart failure and severe LVEF impairment, without complaints about sleep-disordered breathing (SDB) we wanted to test the efficacy of two ventilation modes: bi-level PPV spontaneous/timed (S/T) and ASV on CSR, sleep quality, and LVEF.

Section snippets

Subjects

A total of 129 patients with stable, pharmacologically treated CHF (LVEF < 45%, New York heart association [NYHA] functional class II–III) were screened in order to detect CSR, using an ambulatory polygraph with oximetry, heart rate, oronasal airflow, snoring sounds, and abdominal respiratory effort (Embletta; Embla Systems, Denver, Co, USA). Visual evaluation revealed that 42 patients had CSR with a respiratory disturbance index (RDI) > 15/h, with less than 20% obstructive respiratory events.

Results

The study showed a significant reduction in CSR for all patients receiving either mode of therapy. Nevertheless, in five patients we detected persistent SDB (> 15/h) under therapy (3 VPAP, 2 ASV). Three patients demonstrated an appreciable decrease in CSAI, but ultimately were unable to achieve an efficient adaptation setting to the variable positive airway pressure (VPAP) therapy. One patient had a higher RDI after VPAP therapy than before. Results for breathing, oxygen saturation, and

Discussion

In a patient population, primarily with no complaint about SDB and with stable chronic heart failure with severe LVEF impairment, we first selected patients who had CSR. For this selection we used an ambulatory polygraph, which was acceptable to these patients, and then confirmed the diagnosis by cardiorespiratory polysomnography. In a 6-week treatment trial we found an increase in LVEF on the basis of effective PPV treatment of CSR using two titration nights in the sleep laboratory. These

Acknowledgement

This study was supported in part by an unrestricted grant from Resmed, Germany.

References (34)

  • M. Arzt et al.

    Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP)

    Circulation

    (2007)
  • M.T. Naughton et al.

    Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure

    Circulation

    (1995)
  • D.R. Mansfield et al.

    Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure

    Am J Respir Crit Care Med

    (2004)
  • Y. Kaneko et al.

    Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea

    N Engl J Med

    (2003)
  • T.D. Bradley et al.

    Continuous positive airway pressure for central sleep apnea and heart failure

    N Engl J Med

    (2005)
  • S. Javaheri

    CPAP should not be used for central sleep apnea in congestive heart failure patients

    J Clin Sleep Med

    (2006)
  • T. Kasai et al.

    Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with Cheyne-Stokes respiration and central sleep apnea

    Circ J

    (2005)
  • Cited by (86)

    • Noninvasive bilevel positive airway pressure therapy

      2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second Edition
    • Treatment of Breathing-Related Disorders

      2019, Handbook of Sleep Disorders in Medical Conditions
    • The effect of adaptive servo ventilation (ASV) on objective and subjective outcomes in Cheyne-Stokes respiration (CSR) with central sleep apnea (CSA) in heart failure (HF): A systematic review

      2016, Heart and Lung: Journal of Acute and Critical Care
      Citation Excerpt :

      Excel 2010 (Microsoft Corporation) software program was used to organize extracted study data. Of the ten papers included in the review, seven were randomized parallel-group trials35–41 and three were randomized cross-over trials.42–44 Four studies were considered as high quality,35,38–40 whereas six studies were considered as good quality (Tables 3 and 4).36,37,41–44

    • Current treatment approaches and trials in central sleep apnea

      2016, International Journal of Cardiology
      Citation Excerpt :

      It follows that this modality is effective for treatment of combined obstructive and central sleep apnea, a common occurrence in HF patients [49–51]. Since its introduction, numerous small short term trials, as well as observational studies in Europe and Japan using ASV in HF patients with CSA reported improved cardiac function, exercise capacity, NYHA classification and BNP [28,52–56]. These studies led to the wide use of ASV clinically and provided the justification for large trials addressing the effect of ASV on cardiac function.

    View all citing articles on Scopus
    View full text